The ability to significantly reduce lifetime risk for selected forms of cancer is dependent, in part, on our ability to develop and bring to market agents that can clearly reduce that risk ??? in the same way that cholesterol-lowering agents have been able to reduce risk for certain types of cardiovascular disease.